Reduced levels of circulating HDL-linked biomarkers, specifically apoA-I and HDL cholesterol, are linked to more advanced liver disease, systemic inflammation, infectious complications, and organ failure in cirrhosis with an increased risk of mortality20. Here, APOA1 is linked to liver disorder.